Enzo Biochem, Inc. filings document the public-company record for a life sciences tools issuer and its common stock. The filing record includes a Form 15 certification and notice covering termination of Exchange Act registration under Section 12(g) and suspension of reporting duties under Sections 13 and 15(d) for the company’s common stock.
Enzo’s current reports also cover material-event disclosures, material agreements, shareholder voting matters, capital-structure disclosures, governance matters, and operating and financial results tied to its life sciences business and corporate status.
Enzo Biochem, Inc. (ENZ) entered into and completed a merger in which Bethpage Merger Sub merged into Enzo, and Enzo became a wholly owned subsidiary of Bethpage Parent.
At the effective time on August 20, 2025, each outstanding share was converted into the right to receive $0.70 in cash per share (subject to withholding). Vested restricted stock units held by directors or vested-but-unsettled RSUs were converted into a cash payment equal to the number of underlying shares multiplied by $0.70. Unvested RSUs and all outstanding options were canceled without consideration. As a result, the reporting persons state they no longer beneficially own any Enzo securities and ceased to own more than 5% of the class.
Enzo Biochem, Inc. filed an S-8 post-effective amendment covering previously filed registration statements for shares issuable under various employee benefit and equity compensation plans. The filing lists multiple prior registration statements dating from 1983 through 2021 that pertain to aggregate share amounts under plans including the 1994 Plan, 1999 Plan, 2011 Incentive Plan, Profit Sharing Plan and inducement awards. The filing is signed by Chief Financial Officer Patricia Eckert.
Enzo Biochem, Inc. filed an S-8 post-effective amendment covering previously filed employee benefit and equity compensation registration statements. The filing lists multiple historical registrations that together authorize issuance under various plans, including registered amounts of 988,951, 950,000, 1,000,000, 2,000,000, 3,000,000, 1,000,000, 2,000,000, 1,000,000, 4,000,000 and an aggregate 960,000 shares tied to inducement awards. The document is a routine update that consolidates past registration statements for employee plans and is signed by Patricia Eckert, Chief Financial Officer.
Enzo Biochem, Inc. filed an S-8 post-effective amendment covering prior employee equity registration statements. The filing lists a series of historic registrations that together cover multiple equity plans, including a 4,000,000-share registration under the 2011 Incentive Plan and a separate 960,000-share registration
Enzo Biochem, Inc. (ENZ) filed an S-8 post-effective amendment that catalogs prior employee equity registration statements covering multiple stock plans. The filing lists historic registrations dating from 1983 through 2021, including specific registrations for 988,951, 950,000, 1,000,000, 2,000,000, 3,000,000, 4,000,000 and a 960,000-share registration tied to inducement awards granted on November 8, 2021. The document is an administrative update to available shares for employee benefit and incentive plans.
Enzo Biochem, Inc. filing confirms classification as a non-accelerated filer and smaller reporting company and lists prior SEC registration statements related to employee benefit and equity compensation plans spanning 1983 through 2021. The filing enumerates multiple registration statement numbers and aggregate share amounts registered under various plans, and is signed by the Chief Financial Officer, Patricia Eckert.
Enzo Biochem, Inc. filed an S-8 post-effective submission that lists prior registration statements covering shares of its common stock issuable under various employee benefit and equity incentive plans. The filing enumerates multiple prior registration statements (1983, 1992, 1994, 1995, 1999, 2002, 2005, 2011, 2014, 2018, 2020, 2021) and specifies aggregate share amounts for several plans. The document is signed by Patricia Eckert, Chief Financial Officer.